The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial
Open accessAbstract
Raloxifene is a selective estrogen receptor modulator that in experimental animals acts as an estrogen receptor antagonist in breast and endometrium but as an estrogen receptor agonist in the skeletal and cardiovascular systems. We conducted a 1-year prospective, randomized, double-blind trial in 143 postmenopausal osteoporotic women (mean ± SD age, 68.4 ± 5.0 years) with at least one prevalent vertebral fractures and low bone mineral density (BMD), comparing groups receiving raloxifene at 60 mg/day (RLX60) or 120 mg/day (RLX120) and a control group receiving supplements of 750 mg/day of calcium and 400 IU/day of vitamin D. There were no differences among groups in the occurrence of uterine bleeding, thrombophlebitis, breast abnormalities, or increased endometrial thickness (assessed by ultrasonography). As compared with controls, the changes in values over 1 year for RLX60 and RLX120, respectively, were significant for serum bone alkaline phosphatase (−14.9%, −8.87%), serum osteocalcin (−20.7%, −17.0%), and urinary C-telopeptide fragment of type I collagen/creatinine (−24.9%, −30.8%), markers of bone turnover; for serum total cholesterol (−7.0% for RLX60) and low density lipoprotein cholesterol (LDL) (−11.4% for RLX60) and for the LDL/HDL cholesterol ratio (−13.2%, −8.3%). BMD increased significantly in the total hip (1.66% for RLX60) and ultradistal radius (2.92%, 2.50%). There were nonsignificant trends toward increases over controls in BMD for lumbar spine, total body, and total hip (for RLX120). Using a >15% cutoff definition, raloxifene had no effect on incident fractures, but using a >30% cutoff, there was a dose-related reduction (p = 0.047). We conclude that raloxifene therapy is well tolerated, reduces serum lipids, and does not stimulate the uterus or breasts. It has beneficial effects on bone, although, under the conditions of this study, these appear to be of a smaller magnitude than have been reported with estrogen therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“Most importantly, there are recent data that support strongly the contention that long-term estrogen therapy is associated with an increased risk for breast cancer.((25)) Even though this is still a subject of debate,((26)) the issue has had wide coverage in the mass media, and a general TABLE 5.”
Background
Cited by
Manolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517
Compston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 511
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group (2002) · Endocrine Reviews · doi:10.1210/edrv.23.4.0486 · Cited by 471
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Metadata
- Authors
- Lufkin, E. G., Whitaker, M. D., Nickelsen, T., Argueta, R., Caplan, R. H., Knickerbocker, R. K., & Riggs, B. L.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-11-01
- Volume
- 13
- Issue
- 11
- Pages
- 1747-1754
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2049765534
- Cited by
- 237
- References
- 1
- FWCI
- 20.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial. https://app.cochat.ai/papers/10.1359/jbmr.1998.13.11.1747
- The paper
- Lufkin, E. G., Whitaker, M. D., Nickelsen, T., Argueta, R., Caplan, R. H., Knickerbocker, R. K., & Riggs, B. L. (1998). Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1998.13.11.1747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.